These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 29169526)

  • 1. Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1.
    Iwata T; Yamamoto A; Hara K
    J Thorac Oncol; 2017 Dec; 12(12):e205-e207. PubMed ID: 29169526
    [No Abstract]   [Full Text] [Related]  

  • 2. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
    Haratake N; Toyokawa G; Tagawa T; Kozuma Y; Matsubara T; Takamori S; Akamine T; Yamada Y; Oda Y; Maehara Y
    Anticancer Res; 2017 Oct; 37(10):5713-5717. PubMed ID: 28982891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer.
    Catania C; Passaro A; Rocco EG; Spitaleri G; Barberis M; Noberasco C; Signore ED; Travaini L; de Marinis F
    Clin Lung Cancer; 2016 Sep; 17(5):e179-e183. PubMed ID: 27349506
    [No Abstract]   [Full Text] [Related]  

  • 4. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
    Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
    World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features.
    Ochi M; Miyamoto S; Terada Y; Furuhata Y; Awano N; Izumo T; Ikushima S; Bae Y; Kumasaka T; Kunito H
    Intern Med; 2018 Jun; 57(12):1773-1777. PubMed ID: 29434118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient.
    Shirasu H; Ono A; Takahashi T
    J Thorac Oncol; 2017 Apr; 12(4):e33-e34. PubMed ID: 28343544
    [No Abstract]   [Full Text] [Related]  

  • 7. A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages.
    Watanabe H; Ohashi K; Nishii K; Seike K; Makimoto G; Hotta K; Maeda Y; Kiura K
    Intern Med; 2019 Oct; 58(20):3033-3037. PubMed ID: 31292383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Mismatch Repair-Deficient Hepatoid Adenocarcinoma of the Lung Responding to Anti-PD-L1 Durvalumab Therapy Despite no PD-L1 Expression.
    Basse V; Schick U; Guéguen P; Le Maréchal C; Quintin-Roué I; Descourt R; Simon H; Uguen A; Quéré G
    J Thorac Oncol; 2018 Jul; 13(7):e120-e122. PubMed ID: 29935850
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.
    Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Yoshida H; Yagi Y; Sakamori Y; Nagai H; Hirai T; Kim YH
    Sci Rep; 2017 Mar; 7():45124. PubMed ID: 28332580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
    Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
    J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma.
    Nakahara Y; Fukui T; Shirasawa M; Harada S; Kusuhara S; Takakura A; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Masuda N; Inukai M; Sekiguchi T; Naoki K
    Intern Med; 2018 Nov; 57(21):3149-3152. PubMed ID: 29877291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.
    Tanizaki J; Hayashi H; Kimura M; Tanaka K; Takeda M; Shimizu S; Ito A; Nakagawa K
    Lung Cancer; 2016 Dec; 102():44-48. PubMed ID: 27987588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
    Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P
    Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report.
    Pluchart H; Pinsolle J; Cohen J; Ferretti GR; Bedouch P; Giaj Levra M; Toffart AC; Moro-Sibilot D
    J Med Case Rep; 2017 Jul; 11(1):183. PubMed ID: 28679408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis.
    Kudo F; Watanabe Y; Iwai Y; Miwa C; Nagai Y; Ota H; Yabe H; Demitsu T; Hagiwara K; Koyama N; Koyama S
    Intern Med; 2018 Aug; 57(15):2217-2221. PubMed ID: 29526968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.
    Matter-Walstra K; Schwenkglenks M; Aebi S; Dedes K; Diebold J; Pietrini M; Klingbiel D; von Moos R; Gautschi O;
    J Thorac Oncol; 2016 Nov; 11(11):1846-1855. PubMed ID: 27311996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment with nivolumab for lung cancer with low expression of PD-L1 and prominent tumor-infiltrating B cells and immunoglobulin G.
    Suyama T; Fukuda Y; Soda H; Ogawara D; Iwasaki K; Hara T; Yoshida M; Harada T; Umemura A; Yamaguchi H; Mukae H
    Thorac Cancer; 2018 Jun; 9(6):750-753. PubMed ID: 29667757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.